Strategies for success in the biobetter market
How can you successfully position biobetter products in the increasingly crowded branded biologic/biosimilar space?
With the prospect of improving patient adherence, meeting unmet clinical need and increasing revenues, investment in the biobetter pipeline has grown rapidly. Yet biobetter products need to bring some serious clinical and cost saving advantages if they are to get stakeholder support and make a return on investment. Success depends on navigating an undefined regulatory pathway, avoiding IP minefields and ultimately persuading stakeholders that the benefits are worth the cost.
In The Future of Biobetters, senior industry experts from leading pharma companies and organisations identify the challenges facing this emerging sector and provide practical and actionable insights for achieving commercial success.
No one can agree exactly what a biobetter is. For some, it is a better safety profile, for others it is improved formulations and dosages that improve patient convenience and compliance. Biosuperior protein therapeutics is a definition preferred by others. Despite being sandwiched between originator biologics and biosimiliars, and with no standardised regulatory definition, the biobetter sector is carving out a significant market niche and attracting considerable investment and interest.
“If the company developing the biobetter has correctly identified the unmet need associated with the originator, and the unmet need is seen as a significant failing by either the healthcare provider or the patients, then biobetters can be seen as a significantly differentiated product. Market share will depend very much on the improvements and safety profile of the biobetter versus the originator. If these are significant then it may be possible to take a very high market share.”
Science Director of Bioprocess Characterisation at Albumedix
Analytics Lead at a leading biopharmaceutical company
“They are two different businesses. Their target markets and pricing strategies can differ. In the biosimilar business, the main criterion is to increase the treatment accessibility by reducing the cost. Emerging markets and the Rest-of-the-World are the markets that biosimilars have good potential to grow, whereas regulated markets such as the US, Europe, Japan, Australia and New Zealand have good potential for biobetters. There is a business opportunity for both, separately”
Senior Vice President at Stelis Biopharma
This critical intelligence is available for immediate download — order your copy now
Need more information? Contact a consultant for an executive summary and sample pages from the report.